Pharmacokinetics (PK) and exposure-response (E-R) analysis of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC) who have not received prior chemotherapy for their metastatic disease.

Lu D, Li C, Polhamus D, French JL, Riggs MM, Agarwal P, Chen SC, Wang X, Smitt M, Patre M, Strasak A, Chernyukhin N, Quartino AL, Jin JY, Girish S.

Presented at the 7th Annual American Conference on Pharmacometrics

October 2016

© 2016 Metrum Research Group LLC